BAT Announces Repurchase of 74,186 Shares as Part of Ongoing Buyback Program

Nov.28.2024
BAT Announces Repurchase of 74,186 Shares as Part of Ongoing Buyback Program
BAT has repurchased 74,186 shares from Merrill Lynch International, reducing its share count to 2.21 billion, enhancing shareholder value through potential EPS growth.

British American Tobacco PLC (BAT) has repurchased 74,186 ordinary shares at an average price of 2,999.38 pence per share from Merrill Lynch International. This repurchase forms part of the Company's ongoing buyback program, as announced on 28 November.

 

The transaction, initially announced on 18 March 2024 and authorized by shareholders at the Company's Annual General Meeting on 24 April 2024, was completed on 27 November 2024.

 

Key details of the transaction are as follows:

 

  • Date of purchase: 27 November 2024

 

  • Number of shares repurchased: 74,186

 

  • Highest price paid per share: 3,010.00 pence

 

  • Lowest price paid per share: 2,978.00 pence

 

  • Volume weighted average price paid per share: 2,999.38 pence

 

After the purchase and cancellation, BAT's total number of ordinary shares in issue (excluding treasury shares) will be 2,210,937,032.

 

This reduction in shares is part of a strategic decision designed to enhance shareholder value by potentially increasing earnings per share.

 

Additionally, shareholders may need to assess whether they are required to notify any changes to their interest in the company, in accordance with the FCA's Disclosure Guidance and Transparency Rules.

 

FDA Details Carcinogenicity Tiering and ELCR Framework as Small Manufacturers Press for Predictability
FDA Details Carcinogenicity Tiering and ELCR Framework as Small Manufacturers Press for Predictability
During the “Toxicological Profile” session at FDA’s Feb 10 PMTA roundtable, officials outlined the carcinogenicity tiering system and Excess Lifetime Cancer Risk (ELCR) framework used in ENDS reviews under the APPH standard. Small manufacturers questioned database transparency, exposure assumptions, and the existence of clear compliance benchmarks. FDA reiterated toxicological risk is assessed case by case within a broader population-level determination.
Feb.11
UK reminds vaping firms to apply for new excise duty registration from April 2026
UK reminds vaping firms to apply for new excise duty registration from April 2026
HMRC has issued a reminder urging vaping manufacturers, importers and warehouse operators to prepare for registration under the UK’s new Vaping Products Duty, with applications opening in April 2026 and the duty taking effect in October.
Feb.10
BAT CEO: to ramp up ‘next-generation’ tobacco capacity in Italy, plans €500 mln investment in Trieste plant by 2027
BAT CEO: to ramp up ‘next-generation’ tobacco capacity in Italy, plans €500 mln investment in Trieste plant by 2027
British American Tobacco (BAT) CEO Tadeu Marroco said the group will continue to invest in equipment and technology in Italy and expand capacity for next-generation tobacco products such as e-cigarettes and heated tobacco. BAT’s Trieste innovation hub is slated to receive a total investment of 500 million euros by 2027 and add 16 new production lines.
Feb.03 by 2FIRSTS.ai
Maryland middle school incident: 11-year-olds found with a THC vaping device; juvenile citations issued
Maryland middle school incident: 11-year-olds found with a THC vaping device; juvenile citations issued
The BayNet reports that on Feb. 5 at about 1:35 p.m., an 11-year-old student at Davis Middle School in Waldorf, Maryland, was found in possession of a vaping device containing THC. Further investigation found that two other 11-year-old students also possessed the same vaping device at different points during the day.
Feb.09 by 2FIRSTS.ai
2Firsts Interview | Bengt Wiberg: Why the Oral Health Risks of Nicotine Pouches Merit Further Study
2Firsts Interview | Bengt Wiberg: Why the Oral Health Risks of Nicotine Pouches Merit Further Study
As nicotine pouches gain global traction as a lower-risk alternative to smoking, questions are emerging about their potential oral health effects. In a 2Firsts interview, Stingfree AB founder Bengt Wiberg discusses why gum irritation and oral lesions warrant closer scrutiny within the broader framework of tobacco harm reduction.
Jan.06
BREAKING: China Brings Nicotine Pouches Under Tobacco Monopoly Regulation, Signaling Major Shift for Oral Products
BREAKING: China Brings Nicotine Pouches Under Tobacco Monopoly Regulation, Signaling Major Shift for Oral Products
China has for the first time issued clear regulatory rules for nicotine pouches and other oral nicotine products, formally classifying them under the tobacco monopoly alongside cigarettes and tobacco, ending a long-standing legal grey zone and laying the regulatory groundwork for their potential domestic launch.
Jan.09 by Alan Zhao | 2Firsts Perspectives